Brain
shrinkage in pediatric patients with attention deficit hyperactivity
disorder is not caused by medication
The brains of children and adolescents
with attention deficit hyperactivity disorder are 3 to 4 percent smaller
than those of healthy children but drug treatment is
not the cause, according to an article in the October 9th issue of
the Journal of the American Medical Association.
Researchers at the U.S. National Institute
of Mental Health included previously never-medicated children among
the patients studied over the course of the 10-year study. Magnetic
resonance imaging found "strikingly smaller" white matter
volumes in children who had not taken stimulant drugs. Still, the
course of brain development in patients with the disorder paralleled
that of normal subjects, suggesting that whatever caused the disorder
happened earlier in development.
In 1991, investigators enrolled 152 children
(89 male, 63 female) with attention deficit hyperactivity disorder
aged 5 to 18 years. They used magnetic resonance imaging to study
the brains of the pediatric patients and 139 age- and gender-matched
controls, who were children and adolescents without the disorder.
Most patients were scanned at least twice, and some up to four times
over the decade.
As a group, the pediatric psychiatric patients
showed 3 to 4 percent smaller brain
volumes in all regions. The more severe the symptoms of the disorder
(as rated by parents and clinicians), the smaller were their frontal
lobes, temporal gray matter, caudate nucleus, and cerebellum.
Although medicated patients' white matter
volume did not differ from that of controls, white matter volume
was abnormally small in 49 never-medicated patients. These findings
held statistically even after adjustment for the fact that the unmedicated
children tended to be younger.
"There is no evidence that medication harms the brain,"
said Xavier Castellanos, M.D., the lead author. "It's possible
that medication may promote brain maturation."
White matter volume over time represents one
gauge of the brain's maturation. "Children with attention deficit
hyperactivity disorder are often described as less mature than their
peers and this may relate to delays in white matter maturation,"
explained Castellanos. "While we do not yet know if medication
can accelerate white matter growth, we do know that treating children
with medication helps their behavior while they're taking the drugs.
There is no evidence that it helps after they stop." Animal
studies will be required to determine the impact of medication on
brain maturation, he added.
In the current study, the psychiatric patients'
developmental trajectories for nearly all brain regions paralleled
growth curves for controls, but on a slightly lower track.
"Fundamental developmental processes
active during late childhood and adolescence are essentially healthy
[in patients with the disorder]," asserted the researchers.
"Symptoms appear to reflect fixed earlier neurobiological insults
or abnormalities." Evidence suggests that the disorder runs
in families and may have genetic roots.
As might be expected with hyperactive subjects,
the investigators had to discard 50 of 594 total scans due to blurring
by motion in the scanner. Volumes of various brain structures and
tissue were measured and analyzed by an automated system incorporating
more than 100 networked computer workstations, developed in collaboration
with researchers at the Montreal Neurological Institute.
Although the research group at the National
Institute of Mental Health had earlier thought that only certain
brain structures were smaller in affected patients, this largest
and most sophisticated study found that the whole brain is affected.
It's possible that a recently discovered gene that determines brain
size could play a role in the disorder, Castellanos suggested.
He also suspects that what is now called one
disorder may ultimately prove to be a group of disorders with different
causes. To identify these subtypes, he suggests that the field begin
studying "endophenotypes," factors that may predict the
risk of the disorder in the same way that cholesterol predicts the
risk of heart disease.
"Magnetic resonance imaging remains a
research tool and cannot be used to diagnose attention deficit hyperactivity
disorder in any given child, due to normal genetic variation in
brain structure," noted another coauthor. "The measured
influence of [the disorder] on brain volume can only be discerned
statistically across groups of children with and without the disorder."
|